BioMarin Pharmaceutical (BMRN) is back in focus after new VOXZOGO and BMN 333 data at ENDO 2026, adding fresh context to a stock that recently reacted to mixed quarterly results and updated guidance.

Alongside the ENDO 2026 update and a recent quarter that was mixed but included higher guidance, BioMarin Pharmaceutical’s share price shows short-term momentum building, with a 7.88% seven-day share price return and a 7.68% 90-day share price return, while the three-year total shareholder return is still down 31.93%.

If VOXZOGO and BMN 333 put you in the mood to scan for more growth stories in healthcare, this could be a good moment to check out 39 healthcare AI stocks

With BioMarin Pharmaceutical now trading at $59.00 and sitting at a sizeable discount to the average analyst price target and intrinsic value estimate, the key question is whether this signals an undervalued stock or a market that is already pricing in future growth.

Most Popular Narrative: 33% Undervalued

Compared with BioMarin Pharmaceutical’s last close at $59.00, the most followed narrative points to a fair value near $87.85, framing the current discount as driven by detailed assumptions on future cash flows and profitability.

Recent research updates present a split picture on BioMarin, with analysts reassessing price targets as they balance strong Voxzogo Phase 3 data against a more cautious stance on BMN401 in ENPP1 deficiency.

Bullish Takeaways

• Bullish analysts see the Voxzogo Phase 3 results as a key driver for potential growth, highlighting the +2.33 cm/yr improvement in annualized growth velocity at Week 52 as encouraging for the drug's use in an additional indication.

The fair value depends on how fast VOXZOGO and other therapies scale, how margins shift over time, and which earnings path plays out, as the spread between bullish and cautious scenarios is wide.

Result: Fair Value of $87.85 (UNDERVALUED)

However, BioMarin Pharmaceutical’s story also depends on how competition in rare disease treatments evolves and whether higher R&D and SG&A spending weighs on future profitability.

Another View on BioMarin Pharmaceutical’s Valuation

While the analyst narrative and SWS DCF model both arrive at an undervalued view for BioMarin Pharmaceutical, the DCF result is far more aggressive, with a fair value estimate of $211.26 versus the $87.85 analyst target. That gap raises a simple question for investors: which assumptions do you trust more.

Next Steps

Seeing both potential and concern around BioMarin Pharmaceutical, this is a moment to move quickly, review the full picture, and weigh the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond BioMarin Pharmaceutical?

If BioMarin Pharmaceutical has sharpened your focus, do not stop here. Use the tools available to compare other opportunities and pressure test your next moves with data driven screens.

• Zero in on stability and staying power by reviewing companies in the 71 resilient stocks with low risk scores.
• Hunt for quality at a markdown by checking stocks highlighted in the 44 high quality undervalued stocks.
• Spot potential future standouts early by scanning the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.